eCommons@AKU
Department of Pathology and Laboratory Medicine

Medical College, Pakistan

January 2006

Screening for cystic fibrosis: The importance of
using the correct tools
Uzma Shah
Aga Khan University

Tariq Moatter
Aga Khan University, tariq.moatter@aku.edu

Follow this and additional works at: https://ecommons.aku.edu/
pakistan_fhs_mc_pathol_microbiol
Part of the Microbiology Commons, and the Pathology Commons
Recommended Citation
Shah, U., Moatter, T. (2006). Screening for cystic fibrosis: The importance of using the correct tools. Journal of Ayub Medical College,
18(1).
Available at: https://ecommons.aku.edu/pakistan_fhs_mc_pathol_microbiol/1001

J Ayub Med Coll Abbottabad 2006;18(1)

SCREENING FOR CYSTIC FIBROSIS: THE IMPORTANCE OF USING
THE CORRECT TOOLS
Uzma Shah, Tariq Moatter
Director of Pediatric Gastroenterology, Hepatology and Nutrition Department of Pathology and Microbiology, The Aga Khan
University, Karachi

Background: Cystic Fibrosis (CF) is a potentially lethal genetic disorder. The most frequent
mutation worldwide in the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) gene
is designated as the Delta F508 mutation. This mutation was found in only 33% of Pakistani
patients studied. Since the common Pakistani mutations remain to be identified, appropriate
screening tools are required to identify disease. Sweat chloride determinations remain the gold
standard for diagnosing CF. This study was done to emphasize the importance of using the correct
tests. Methods: The study was conducted at the Aga Khan University Hospital. The CFTR delta
F508 mutation was tested on blood samples from patients suspected with CF. Sweat chloride
analysis using pilocarpine iontopharesis was done with a positive value of greater than 60 meq/L.
Results: 57 pediatric samples were screened for the delta F508 mutation and were positive in only
10.6 % of all patients tested. 12/57 (21%) had a preliminary sweat test. 6/12 (50%) of these
patients had an abnormal sweat test and 3/6 patients with an abnormal sweat chloride (50 %) had
deltaF508 mutations - 2/6 (33%) were homozygotes and 1 was a compound heterozygote. Since
79% did not have a sweat test, it was difficult to assess whether this subset of patients had cystic
fibrosis with a CFTR mutation other than the delta F508 tested or no CF. Conclusion: Sweat
chloride analysis is critical to distinguish CF from other causes of severe pulmonary and
pancreatic insufficiencies and to define patients requiring further analysis.
Key words: Cystic fibrosis, sweat chloride, mutation analysis

INTRODUCTION
Cystic Fibrosis is the most common autosomal
recessive, potentially lethal genetic disorder,
associated with pulmonary and pancreatic
insufficiency. The abnormality lies in a mutation in
the Cystic Fibrosis Transmembrane Conductance
Regulator (CFTR) gene. More than 1340 mutations
in this gene have been identified worldwide to date.
The most frequent mutation identified is designated
as the Delta F508 mutation. This mutation, which is
present in 70-100 % of CF patients of Caucasian
origin, was found in only 33% of the Pakistani
patients that we have studied so far (1). The CF
mutations in the remaining 66 % of Pakistani patients
have yet to be defined.
Screening tools, such as sweat chloride
analysis, are critical for the identification of those
patients that would require further mutation analysis.
Since the common Pakistani mutations still remain to
be identified, sweat chloride determinations are
extremely important to make a diagnosis of Cystic
fibrosis. This study was done to emphasize the
importance of using the correct screening tools to
establish an unambiguous diagnosis of the disease.

MATERIAL AND METHODS
The study was conducted at the Aga Khan University
Hospital, Karachi, Pakistan over the years 20022003. This is a tertiary care facility that caters to

patients from all over Karachi as well as from other
areas of Pakistan.
Patients with clinical suspicion for CF were
identified. The mutation analysis for CFTR delta
F508 was done on blood samples from all these
patients using the amplification refractory mutation
system and polymerase chain reactions. The delta
F508 test was used as the sole means of diagnosis of
CF for a period of time during which the sweat test
was unavailable due to malfunction of the machine.
The sweat chloride analysis as a screening tool was
therefore used in only some of these patients. The
sweat test used pilocarpine iontophoresis and a
positive value was defined as a sweat chloride of
greater than 60 meq/L. Meconium ileus was also
considered as a positive outcome variable of CF and
these patients were included in the study. We
reviewed the charts of all patients hence screened for
CF.

RESULTS
The Molecular Biology department at the Aga Khan
University received 57 pediatric samples to be
screened for the delta F508 mutation. 61.4% of the
patients tested were suspected to have CF due to
respiratory symptoms, 19.3% for malabsorption and
diarrhea and 8.8 % for problems with failure to
thrive. 3 patients had meconium ileus as a presenting
feature (Table 1). Of all these patients, however,
only 12/57 (21%) patients had a preliminary sweat
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chloride analysis. 6/12 (50%) of those tested with the
sweat chloride analysis had an abnormal sweat
chloride value (71-168, mean 109 meq/L) and 3 of
these 6 patients (50 %) with an abnormal sweat
chloride had delta F508 mutations - 2/6 (33%) were
homozygotes and 1 was a compound heterozygote
(the other mutation is still unknown). Two of the
three patients (66.7%) with meconium ileus had a
homozygous delta F508 mutation. (Table 2) Overall,
the mutation analysis for delta F508 was positive in
only 10.6 % of all the patients tested. Importantly
since 79% did not have an initial sweat chloride
analysis, it would be difficult to assess whether this
subset of patients had cystic fibrosis with a CFTR
mutation other than the delta F508 or no cystic
fibrosis at all. Two of the 57 patients (3.5%) did not
have a screening sweat test but were heterozygous for
delta F508. The sensitivity of the delta F508 test to
diagnose CF when used alone is 43% with a
specificity of a 100%.
When combined with an initial sweat
chloride, the delta F508 mutation analysis was
positive in 50% of those with an abnormal sweat test
result. We suspect that the remaining 50% may have
a CFTR mutation other than the delta F508 tested.
Table 1: Presenting features of patients tested for
Cystic fibrosis
Clinical features
Percentage of
patients (n)
Respiratory symptoms
61.4% (35)
Malabsorption and diarrhea
19.3% (11)
Failure to thrive
8.8% (5)
Liver disease, pancreatic
10.5% (6)
disease and meconium ileus
Table 2: Results of sweat chloride and mutation
analysis
Miscellaneous features

Patients tested for delta F508
Sweat test done
Elevated sweat Chloride
Elevated sweat Chloride with
delta F508 allele
Delta F508 with positive sweat
chloride
Delta F508 in those with no
preliminary sweat test
Patients with meconium ileus
homozygous for delta F508

Number of
patients

57
12/57 (21%)
6/12 (50%)
3/6 (50%)
2/6(33%)
2/45 (4.4%)
2/3 66.7%

DISCUSSION
Cystic fibrosis is a disease with varied clinical
manifestations. Quinton and Knowles et al 2 had first
suggested that the primary defect of cystic fibrosis

may be in chloride transport. The clinical features of
CF stem from the resultant mucous plugging in
various organ systems. Allan et al.3 demonstrated that
meconium ileus was also a feature of cystic fibrosis.
An extension of this is the distal intestinal obstruction
syndrome or DIOS known as a 'meconium ileus
equivalent' that occurs in adolescents and adults with
CF. This obstruction is the consequence of
abnormally viscid mucofeaculant material in the
terminal ileum and colon of these patients.
Pancreatic Insufficiency is an important
feature of cystic fibrosis. However, approximately
15% of CF patients do not have pancreatic
insufficiency, i.e., they are ‘pancreatic sufficient’.
Kerem et al.4 have showed that phenotype/genotype
correlations dictate whether pancreatic insufficiency
or sufficiency is associated with different mutations
at the CF locus.
Mucus plugging in the lungs leads to areas
of atelectasis and superimposed infections. Patients
with cystic fibrosis therefore have an increased
predisposition to the development of pulmonary
disease. The organisms most frequently cultured from
tracheal aspirates from patients with CF include
Pseudomonas and Staphylococcus. Pier et al.5 found
that cultured human airway epithelial cells expressing
the delta-F508 allele of the CFTR gene demonstrate
defective clearance of Pseudomonas that possibly
leads to enhanced pulmonary infection with this
organism in CF.
Focal and mutlilobular biliary cirrhosis are
considered path gnomonic of liver disease in CF6.
The prevalence rates and the risk factors for the
development of CF liver disease have varied
considerably. 7 It is suggested that gene modifiers
may influence disease expression and Gabolde et al
have 8 demonstrated that the presence of cirrhosis in
patients with cystic fibrosis may be associated with
either homozygous or compound heterozygous
mutant mannose-binding lectins.
Congenital bilateral absence of the vas
deferens as a cause of male infertility has also been
described in cystic fibrosis.

SCREENING
Several guidelines have been prepared worldwide
concerning screening for the cystic fibrosis gene 9.
Screening tools considered have included the
immune reactive trypsin test and the sweat chloride
analysis.
Newborn babies with CF have abnormally high levels
of immunoreactive trypsin (IRT) in serum, which has
been the basis for its use as a screening tool. The
IRT test has a 90% detection rate for CF and a 0.3%
false positive rate.
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Other tests that have been used for screening for
cystic fibrosis include measurement of nasal potential
difference and conductance through mucosal biopsies
when placed in Ussing chambers.
The only screening tool currently available
in Pakistan is the sweat chloride analysis. The
Pilocarpine Sweat Test remains the gold standard for
diagnosis. This test measures the concentration of
chloride in the sweat. In the majority of CF patients
with typical features and identified mutations the
sweat test is diagnostic. A positive sweat test is then
followed by a mutation analysis for the predominant
mutations in the population.
The indications for sweat testing include
clinical features suggestive of CF, a family history of
CF, a positive newborn screening test (such as IRT)
and the suspicion of an atypical phenotype. A
positive result is described as a sweat chloride of
greater than 60 mmol/L, equivocal values are those
between 40-60 mmol/L and a negative test is
described as values less than 40 mmol/L. A value of
40-60 mmol/L in infancy is however considered
suspect for CF 9,10. Borderline sweat results are seen
with some mutations such as in R117H, R334W, and
P67L 11,12. Patients with the F508/S1235R may have
negative sweat tests.
The sweat test can be done in term infants
older than 7 days of age but preferably should be
done in infants after 2 weeks of age and when they
are greater than 3 kg in weight13,14. In a recent
population based study in infants, of the 98 CFscreened-positive affected infants for whom sweat
results had been reported, 84/98 (86%) had values
that were clearly positive and 13 of the remaining 14
had sweat-test results that are consistent with
expectations for a particular CF genotype 15.
The diagnosis of CF can however remain
uncertain in patients with clinical features of CF but
intermediate sweat chloride values and the absence of
identified mutations. It is also important to note that
the sweat chloride concentration does not correlate
with disease severity and a lower concentration does
not necessarily predict a milder pulmonary course in
patients with cystic fibrosis 16,17.
A positive sweat chloride value is an
important tool to distinguish CF from other causes of
severe pulmonary and pancreatic insufficiencies. It
also serves to define those patients who require
further mutation analysis. In the New England
Newborn Screening program, 50% of the patients
were identified by Delta F508 testing alone while
75% were identified when the mutation analysis was
expanded to include several genetic mutations18.
Since, 79% of our patients tested for delta F508, with
symptoms suggestive of CF, did not have a
preliminary sweat test it was very difficult to assess

whether this subset of patients had CF with a CFTR
mutation other than delta F508 or they had a disease
other than cystic fibrosis. When combined with an
initial sweat chloride, the delta F508 mutation
analysis was positive in 50% of those with an
abnormal sweat test result. We suspect that the
remaining 50% may have a CFTR mutation other
than the delta F508 tested. We are now in the process
of studying the common mutations in CF in our
population.
Only a small fraction 3.5% of the 57 patients
in this study had a positive mutation analysis in the
absence of a preliminary screening sweat chloride.

SUMMARY
Since delta F508 is not present in 100% of Pakistani
CF patients, making the diagnosis of CF on the basis
of the presence of one mutation alone would
therefore lead to many false negative diagnoses. We
are in the process of identifying the common
mutations in our population that will help in the
establishment of a diagnosis of CF. In the absence of
other screening tests in Pakistan, sweat chloride
analysis therefore serves as an integral screening tool
for CF.
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